Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 1315432, 11 pages
https://doi.org/10.1155/2017/1315432
Research Article

Effectiveness of Traditional Chinese Medicine Compound JieDuTongLuoShengJin Granules Treatment in Primary Sjögren’s Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

1Department of Rheumatology and Immunology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
2Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
3Department of Ophthalmology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China

Correspondence should be addressed to Luan Xue; moc.361@oclex

Received 27 February 2017; Revised 5 May 2017; Accepted 5 June 2017; Published 10 July 2017

Academic Editor: Lesley Ward

Copyright © 2017 Ben Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Meijer, P. M. Meiners, J. J. R. H. Slater et al., “Health-related quality of life, employment and disability in patients with sjögren's syndrome,” Rheumatology, vol. 48, no. 9, pp. 1077–1082, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. C. G. Helmick, D. T. Felson, R. C. Lawrence et al., “Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I,” Arthritis & Rheumatism, vol. 58, no. 1, pp. 15–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Wang, Z. G. Wang, and F. L. Tang, “Expression of chemokine in the labial glands of patients with Sjogren’s syndrome (in Chinese),” National Medical Journal of China, vol. 83, no. 3, pp. 220-221, 2003. View at Google Scholar
  4. L. T. H. Jacobsson, T. E. Axell, B. U. Hansen et al., “Dry eyes or mouth-an epidemiological study in Swedish adults, with special reference to primary Sjögren's syndrome,” Journal of Autoimmunity, vol. 2, no. 4, pp. 521–527, 1989. View at Publisher · View at Google Scholar · View at Scopus
  5. V. Devauchelle-Pensec, X. Mariette, S. Jousse-Joulin et al., “Treatment of primary Sjögren syndrome with rituximab: a randomized trial,” Annals of Internal Medicine, vol. 160, no. 4, pp. 233–242, 2014. View at Publisher · View at Google Scholar
  6. S. Bowman, C. Everett, and M. Bombardieri, “Preliminary Results of a Double-Blind Randomised Trial of Rituximab Anti-B-Cell Therapy in Patients with Primary Sjogrens Syndrome,” Arthritis Rheumatol, vol. 67, supplement 10, 2015. View at Google Scholar
  7. S. D. Vita, L. Quartuccio, R. Seror et al., “Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study,” Rheumatology, vol. 54, no. 12, pp. 2249–2256, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Ramos-Casals and J. Font, “Primary Sjögren syndrome,” in Current Diagnosis and Treatment in Rheumatology, J. Imboden, D. Hellmann, and J. Stone, Eds., vol. 304, McGraw-Hill, New York, NY, USA, 2007. View at Publisher · View at Google Scholar
  9. H. Luo, X. Li, J. Liu, F. Andrew, and L. George, “Chinese herbal medicine in treating primary Sjögren's syndrome: a systematic review of randomized trials,” Evidence-based Complementary and Alternative Medicine, vol. 2012, Article ID 640658, pp. 1–22, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Ramos-Casals, G. A. Tzioufas, H. J. Stone, A. Sisó, and X. Bosch, “Treatment of primary Sjögren syndrome: a systematic review,” Journal of the American Medical Association, vol. 304, no. 4, pp. 452–460, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Jian-dong, L. Guo-ling, and X. Luan, “The efficacy and safety of the therapeutic method of detoxicating, relieving meridian and engendering fluid in the treatment of the primary sjogren syndrome,” Chinese Jourmal of Basic Medicine in Traditional Chinese Medicine, vol. 19, no. 1, pp. 70–73, 2013. View at Google Scholar
  12. W. Hu, X. Qian, F. Guo et al., “Traditional Chinese medicine compound ShengJinRunZaoYangXue granules for treatment of primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled clinical trial,” Chinese Medical Journal, vol. 127, no. 15, pp. 2721–2726, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Vitali, S. Bombardieri, R. Jonsson et al., “Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European consensus group,” Annals of the Rheumatic Diseases, vol. 61, no. 6, pp. 554–558, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Seror, P. Ravaud, X. Mariette et al., “EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome,” Annals of the Rheumatic Diseases, vol. 70, no. 6, pp. 968–972, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Seror, P. Ravaud, S. J. Bowman et al., “EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome,” Annals of the Rheumatic Diseases, vol. 69, no. 6, pp. 1103–1109, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Seror, H. Bootsma, A. Saraux et al., “Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI),” Annals of the Rheumatic Diseases, vol. 75, no. 2, pp. 1–8, 2014. View at Google Scholar
  17. C. Dawes, “Circadian rhythms in human salivary flow rate and composition,” The Journal of Physiology, vol. 220, no. 3, pp. 529–545, 1972. View at Publisher · View at Google Scholar · View at Scopus
  18. D. B. Ferguson, A. Fort, A. L. Elliott, and A. J. Potts, “Circadian rhythms in human parotid saliva flow rate and composition,” Archives of Oral Biology, vol. 18, no. 9, pp. 1155–1173, 1973. View at Publisher · View at Google Scholar · View at Scopus
  19. F. R. Burlage, J. Pijpe, R. P. Coppes et al., “Variability of flow rate when collecting stimulated human parotid saliva,” European Journal of Oral Sciences, vol. 113, no. 5, pp. 386–390, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. W. W. Kalk, K. Mansour, A. Vissink et al., “Oral and ocular manifestations in Sjögren's syndrome,” Journal of Rheumatology, vol. 29, no. 5, pp. 924–930, 2002. View at Google Scholar
  21. O. P. van Bijsterveld, “Diagnostic tests in the Sicca syndrome,” Archives of Ophthalmology, vol. 82, no. 1, pp. 10–14, 1969. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Jonsson, P. Vogelsang, R. Volchenkov, A. Espinosa, M. Wahren-Herlenius, and S. Appel, “The complexity of Sjögren's syndrome: Novel aspects on pathogenesis,” Immunology Letters, vol. 141, no. 1, pp. 1–9, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Meijer, P. M. Meiners, A. Vissink et al., “Effectiveness of rituximab treatment in primary sjögren's syndrome: a randomized, double-blind, placebo-controlled trial,” Arthritis and Rheumatism, vol. 62, no. 4, pp. 960–968, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Zhao and F.-T. Zhao, “Clinical observation on effect of total glucosides of paeony combined with hcq in treating patients with primary sjögren’s syndrome,” Henan Traditional Chinese Medicine, vol. 33, no. 4, pp. 530-531, 2013 (Chinese). View at Google Scholar
  25. H.-F. Zhang, P. Hou, and Xiao W.-G., “Clinical observation on effect of total glucosides of paeony in treating patients with non-systemic involved sjögren syndrome,” CJITWM, vol. 27, no. 7, pp. 596–598, 2007 (Chinese). View at Google Scholar
  26. G.-F. Hao, C.-P. Wen, and Y.-S. Li, “Experimental research of the treatments of heat -clearing and detoxication for sicca syndrome,” Chinese Archives of Traditional Chinese Medicine, vol. 30, no. 9, article 2125, 2012. View at Google Scholar
  27. W.-K. Ma, E.-T. Jia, L.-M. Liu et al., “Gene expression of AQP1, AQP5 in Sjogren's syndrome model mice salivary gland, and the therapeutic effect of jiedu huayu herbs,” New Journal of Traditional Chinese Medicine, vol. 43, no. 10, article 111, 2011 (Chinese). View at Google Scholar
  28. W.-K. Ma, Y. Wang, F. Tang et al., “Regulation function of Jiedu Huayu prescriptions for channel water molecules AQP5 protein in the submandibular gland of sjogren's syndrome model mice,” Chinese Journal of Gerontology, vol. 32, no. 1, p. 95, 2012. View at Google Scholar
  29. D. Wang, H. Zhao, and L. Qiuju, “Analysis of the expression of AQP5 in rats with Sjogren syndrome intervened by Detoxicating Medicine, Meridians-relieving Medicine and Engender Fluid Medicine,” China Medical Herald, vol. 9, no. 19, p. 26, 2012. View at Google Scholar
  30. D. Wang, X. Luan, and L. Qiuju, “The preliminary research about the efficacy of the therapeutic method of Detoxicating, Relieving Meridian and Engendering Fluid in sjogren's syndrome rats on the immune function,” Zhejiang Journal of Traditional Chinese Medicine, vol. 46, no. 11, pp. 837–839, 2011. View at Google Scholar
  31. R. Seror, E. Theander, J. G. Brun et al., “Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and Patient indexes (ESSPRI),” Annals of the Rheumatic Diseases, vol. 74, no. 5, pp. 859–866, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Seror, X. Mariette, and S. Bowman, “Accurate detection of changes in disease activity in primary sjogren’s syndrome by the european league against rheumatism Sjogren’s syndrome disease activity index,” Arthritis Care & Research, vol. 62, no. 4, pp. 551–558, 2010. View at Publisher · View at Google Scholar
  33. S. J. Bowman, D. A. Booth, R. G. Platts et al., “Measurement of fatigue and discomfort in primary Sjögren's syndrome using a new questionnaire tool,” Rheumatology, vol. 43, no. 6, pp. 758–764, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. S. J. Bowman, D. A. Booth, R. G. Platts, A. Field, and J. Rostron, “Validation of the Sicca Symptoms Inventory for clinical studies of Sjögren's syndrome,” Journal of Rheumatology, vol. 30, no. 6, pp. 1259–1266, 2003. View at Google Scholar · View at Scopus
  35. C. Vitali, G. Palombi, C. Baldini et al., “Sjögren's syndrome disease damage index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients,” Arthritis and Rheumatism, vol. 56, no. 7, pp. 2223–2231, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. S. J. Bowman, N. Sutcliffe, D. A. Isenberg et al., “Sjögren's Systemic Clinical Activity Index (SCAI) - a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome,” Rheumatology, vol. 46, no. 12, pp. 1845–1851, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. P. M. Meiners, S. Arends, E. Brouwer, F. K. L. Spijkervet, A. Vissink, and H. Bootsma, “Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab,” Annals of the Rheumatic Diseases, vol. 71, no. 8, pp. 1297–1302, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. S.-Q. Shuai and H.-B. Sun, “Treatment of primary Sjogren’s syndrome with hydroxychloroquine,” West China Medical Journal, vol. 23, no. 7, pp. 1281–1283, 2011. View at Google Scholar
  39. H. Hao, “Clinical observation of sjogren's syndrome with the treatment of Radix paeoniae alba total glycosides in combination with hydroxychloroquine,” Hubei journal of traditional Chinese medicine, vol. 32, no. 11, pp. 30-31, 2010. View at Google Scholar
  40. G. Mumcu, M. Biçakçigil, N. Yilmaz et al., “Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren's syndrome,” Oral health & preventive dentistry, vol. 11, no. 3, pp. 229–234, 2013. View at Google Scholar · View at Scopus
  41. S. Yavuz, E. Asfuroǧlu, M. Bicakcigil, and E. Toker, “Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome,” Rheumatology International, vol. 31, no. 8, pp. 1045–1049, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Rihl, K. Ulbricht, R. E. Schmidt, and T. Witte, “Treatment of sicca symptoms with hydroxychloroquine in patients with Sjögren's syndrome,” Rheumatology, vol. 48, no. 7, pp. 796–799, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Cankaya, E. Alpöz, G. Karabulut, P. Güneri, H. Boyacoglu, and Y. Kabasakal, “Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjgren patients: a prospective sample study,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 110, no. 1, pp. 62–67, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. J.-Q. Cao, L.-J. Zhao, W.-G. XIao et al., “Effect of Hydroxychlorquine on IL-1β and TNF-α in non-obese diabetic mice with Sjögren's syndrome,” Chinese Journal of Rheumatology, vol. 10, no. 9, pp. 542–546, 2006 (Chinese). View at Google Scholar
  45. E. K. Akpek, K. B. Lindsley, R. S. Adyanthaya, R. Swamy, A. N. Baer, and P. J. McDonnell, “Treatment of Sjögren's syndrome-associated dry eye. An evidence-based review,” Ophthalmology, vol. 118, no. 7, pp. 1242–1252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. F. B. Vivino, I. Al-Hashimi, Z. Khan et al., “Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed- dose, multicenter trial,” Archives of Internal Medicine, vol. 159, no. 2, pp. 174–181, 1999. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Petrone, J. J. Condemi, R. Fife, O. Gluck, S. Cohen, and P. Dalgin, “A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca,” Arthritis and Rheumatism, vol. 46, no. 3, pp. 748–754, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Gannot, H. E. Lancaster, and P. C. Fox, “Clinical course of primary Sjögren’s syndrome: salivary, oral, and serologic aspects,” The Journal of Rheumatology, vol. 27, no. 8, pp. 1905–1909, 2000. View at Google Scholar
  49. B. K. S. Davidson, C. A. Kelly, and I. D. Griffiths, “Primary Sjogren's syndrome in the North East of England: a long-term follow-up study,” Rheumatology, vol. 38, no. 3, pp. 245–253, 1999. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Pijpe, G. W. Van Imhoff, F. K. L. Spijkervet et al., “Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study,” Arthritis and Rheumatism, vol. 52, no. 9, pp. 2740–2750, 2005. View at Publisher · View at Google Scholar · View at Scopus